Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

KURA – Kura Oncology, Inc.

Float Short %

9.39

Margin Of Safety %

-41

Put/Call OI Ratio

0.03

EPS Next Q Diff

0.54

EPS Last/This Y

-0.22

EPS This/Next Y

0.04

Price

7.66

Target Price

27

Analyst Recom

1.21

Performance Q

22.6

Relative Volume

1.75

Beta

0.16

Ticker: KURA




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25KURA6.220.050.002051
2025-07-28KURA6.20.040.022097
2025-07-29KURA6.360.040.502225
2025-07-30KURA6.30.040.002225
2025-07-31KURA6.050.0713.002292
2025-08-01KURA6.010.090.032318
2025-08-04KURA6.320.080.312420
2025-08-05KURA6.360.090.002490
2025-08-06KURA6.030.090.002490
2025-08-07KURA5.970.090.082591
2025-08-08KURA5.550.090.112593
2025-08-11KURA5.530.091.002825
2025-08-12KURA6.20.090.002843
2025-08-13KURA6.490.090.023024
2025-08-14KURA6.590.090.003034
2025-08-15KURA7.340.090.003055
2025-08-18KURA7.490.030.005407
2025-08-19KURA7.20.020.086301
2025-08-20KURA7.050.033.446527
2025-08-21KURA7.440.030.046572
2025-08-22KURA7.660.030.016588
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25KURA6.2330.9- -2.06
2025-07-28KURA6.2230.9- -2.06
2025-07-29KURA6.3730.9- -2.06
2025-07-30KURA6.3030.9- -2.06
2025-07-31KURA6.0530.9- -2.06
2025-08-01KURA6.0230.9- -2.06
2025-08-04KURA6.3237.3- -1.97
2025-08-05KURA6.3637.3- -1.97
2025-08-06KURA6.0437.3- -1.97
2025-08-07KURA5.9637.3- -1.97
2025-08-08KURA5.5437.3- -1.97
2025-08-11KURA5.5337.3- -1.97
2025-08-12KURA6.20-36.6- -1.97
2025-08-13KURA6.49-36.6- -1.97
2025-08-14KURA6.60-36.6- -1.97
2025-08-15KURA7.34-36.6- -2.18
2025-08-18KURA7.49-1.2-227.6-2.18
2025-08-19KURA7.19-1.299.1-2.18
2025-08-20KURA7.05-1.2184.3-2.18
2025-08-21KURA7.44-1.2-13890.0-2.18
2025-08-22KURA7.66-1.2-235.4-2.24
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25KURA-1.123.2710.22
2025-07-28KURA-1.123.3510.22
2025-07-29KURA-0.603.3510.22
2025-07-30KURA-0.603.3510.22
2025-07-31KURA-0.603.3510.22
2025-08-01KURA-0.603.3510.22
2025-08-04KURA-0.603.2010.22
2025-08-05KURA-0.603.2010.22
2025-08-06KURA-0.603.2010.22
2025-08-07KURA-0.603.2010.22
2025-08-08KURA-0.603.2010.22
2025-08-11KURA-0.603.0710.19
2025-08-12KURA-0.603.079.59
2025-08-13KURA-0.603.079.59
2025-08-14KURA0.573.079.59
2025-08-15KURA0.573.079.59
2025-08-18KURA0.572.969.55
2025-08-19KURA0.602.969.39
2025-08-20KURA0.942.969.39
2025-08-21KURA0.942.969.39
2025-08-22KURA0.942.969.39
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.75

Avg. EPS Est. Current Quarter

-0.64

Avg. EPS Est. Next Quarter

-0.21

Insider Transactions

0.94

Institutional Transactions

2.96

Beta

0.16

Average Sales Estimate Current Quarter

18

Average Sales Estimate Next Quarter

64

Fair Value

4.54

Quality Score

25

Growth Score

25

Sentiment Score

48

Actual DrawDown %

82.2

Max Drawdown 5-Year %

-86.7

Target Price

27

P/E

Forward P/E

PEG

P/S

7.97

P/B

2.17

P/Free Cash Flow

5.4

EPS

-2.26

Average EPS Est. Cur. Y​

-2.24

EPS Next Y. (Est.)

-2.2

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-236.76

Relative Volume

1.75

Return on Equity vs Sector %

-89.2

Return on Equity vs Industry %

-76.3

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.27

EBIT Estimation

-235.4
Kura Oncology, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 192
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
stock quote shares KURA – Kura Oncology, Inc. Stock Price stock today
news today KURA – Kura Oncology, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KURA – Kura Oncology, Inc. yahoo finance google finance
stock history KURA – Kura Oncology, Inc. invest stock market
stock prices KURA premarket after hours
ticker KURA fair value insiders trading